Divisions & Faculty

Background

• Medical School: Eastern Virginia Medical School
• Residency:  Brooke Army Medical Center
• Fellowship:  Walter Reed Hospital

Board Certifications

• American Board of Psychiatry & Neurology
• Child Neurology

Clinical Interests

• Epilepsy
• Neuromuscular Disorders
• ADD
• Behavioral disturbances
• Headache
• Cerebral palsy

• American Academy of Neurology
  American Academy of Pediatrics
  Norfolk Academy of Medicine
  Tidewater Neurological Society
  Tidewater Pediatric Society
  Virginia Neurological Society

Honors and Awards

Hayes Teaching Award, Children’s Hospital of the King’s Daughters                                                     1995
Faculty Teaching Award, Eastern Virginia Medical School                                                                        2005
Faculty Teaching Award, Eastern Virginia Medical School                                                                        2006

Publications

Wiswell TE, Northam RS. Neonatal polycythemia: Frequency of clinical manifestations and other associates findings. Pediatrics, 1 986;78(1 )1 6-30

Wiswell TE, Northam RS. Major congenital neurotogic malformations: a 17 year survey. ADJC, 1990;144:61-67

Northam RS., Singer HS. Tourettism following herpes encephalitis: a case report in a 6-year-old. Neurol, April 1990

Abstracts

Frank LM. Northam RS, Reagan, T. A new progressive Storage Disease with endothelial lysosomal inclusion, myoclonus, focal dermal atrophy, mental retardation and rigidity. Ann Neurol 1994;36:497

Northam RS, Hernandez AW, Litzinger MT, et. al.  Oxcarbazine in infants and young children with partial seizures.  Ped. Neurol. 2005; vol33(5) pg 337-344

Recent Funded Research & Training Grand and Contracts

2004.  XXXXX - A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-  Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy ofXXXXX vs. XXXXX in Pediatric Patients aged 6-12 with Attention-Deficit/Hyperactivity Disorder(ADHD) Principle Investigator: Ralph Northam; Sub-Investigators: L. Matthew Frank, Donald Lewis, Svinder Toor, Larry White

2004XXXXX- A 19-week, randomized, double-blind, multicenter, placebo-controlled safety study to            
evaluate the cognitive and neuropsychological effects of XXXXX, divided in twice daily dosing, as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures; Principle Investigator:  L. Frank; Sub-Investigators: Donald Lewis, Ralph S.
Northam, Svinder S. Toor, Larry White

2004  XXXXX - A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And   Efficacy of XXXXX In Children With Partial Onset Seizures; Principal Investigator:  L. Matthew Frank; Sub-Investigators: Donald Lewis, Ralph S. Northam, Svinder S. Toor,
Larry White

2004 XXXXX – Evaluation of Continuous Symptom Treatment of ADHD; A Placebo-Controlled   Double-Blind Assessment of Morning-Dosed or Evening Dosed XXXXX; Principal Investigator: Donald Lewis; Sub-Investigators: L Matthew Frank, Ralph S. Northam, Svinder S. Toor, Larry White

2004  XXXXX – The Safety and Efficacy of XXXXXin Migraine Prophylaxis: A Double-Blind,   Placebo-Controlled Study in Adolescents; Principal Investigator: Donald Lewis; Sub-
Investigators: L Matthew Frank, Ralph S. Northam, Svinder S. Toor, Larry White

2004 XXXXX– An Open-Label Extension Trial To Determine The Safety and Efficacy of Long-Term   Oral XXXXX In Patients with Partial Seizures; Principal Investigator: L. Matthew Frank; Sub-Investigators: Donald Lewis, Ralph S. Northam, Svinder S. Toor, Larry White

2004  XXXXX - A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of XXXXX As Adjunctive Therapy In Subjects
With Partial Seizures With or Without Secondary Generalization; Principal Investigator:  L. Matthew Frank; Sub-Investigators: Donald Lewis, Ralph S. Northam, Svinder S. Toor, Larry White

2005 - XXXXX A Prospective, Open-Label, Multi-Center Study Evaluating The Safety and   Tolerability of XXXXX in Children Aged 6-12 Previously Treated with XXXXX Product.  Principal Investigator:  R Northam; Sub-Investigators:  LM Frank, D. Lewis,
S. Toor, L. White

2005.  XXXXX A Randomized, Open-Label, Multicenter Study With Open-Label Extension of the  Pharmacokinetics and Safety of XXXXX Administered as the Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1 to 23
Months, Inclusive) With Refractory Partial-Onset Seizures.  Principal Investigator:  R. Northam; Sub-Investigators:  LM Frank, D. Lewis, S. Toor, L. White

2005 -  XXXXX; A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to   Assess the Safety and Tolerability, and Efficacy of XXXXX Oral Liquid and Sprinkle Formulations as an Adjunct To Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months, Inclusive) With Refractory Partial Onset Seizures, with Open-Label
Extension Protocol.  Principal Investigator:  R. Northam; Sub-Investigators:  LM Frank, D. Lewis, S. Toor, L. White

2005.  XXXXX; A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy   and Safety of XXXXX for the Prophylaxis Of Migraine in Pediatric Subjects 12 to 17 Years of Age.  Principal Investigator:  D. Lewis; Sub-Investigators:  LM Frank, R. Northam, S. Toor, L. White

2005  XXXXX Safety and efficacy of XXXXX in subjects with Lennox-Gastaut Syndrome.  Principal Investigator; LM Frank; Sub-Investigators:  D. Lewis, S. Toor, R. Northam, L. White

2005.  XXXXX Safety and effectiveness of open-label XXXXX In subjects with Lennox-Gastaut Syndrome.  Principal Investigator:  LM Frank; Sub-Investigators:  D. Lewis, S. Toor, R. Northam, L. White

2005.  XXXXX; An Open-Label, Multicenter Study of the Long-Term Safety of XXXXX Tablets  for the Treatment of Migraine Prophylaxis in Adolescents.  Principle Investigator: D Lewis; Sub-Investigators:  D Lewis, S Toor, L White, R Northam

2006.  XXXXX.; A 6-Week, Double-Blind, Placebo-Controlled,Parallel Group, Randomized- Withdrawal Study to Evaluate the Continued Efficacy of XXXXX Treatment at Dosages Up to 425 mg/day in Patients with Attention-Deficit/Hyperactivity Disorder Who are Responders to XXXXX Treatment, followed by a 12-Month Open-Label Extension Period. Principal Investigator:  RS Northam; Sub-Investigators:  LM Frank, DE Lewis, SS Toor, LE White, MS Warren

 2006.  XXXXX; XXXXX for Children with Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia.  Principal Investigator:  DW Lewis; Sub-Investigators:  LM Frank, RS Northam, SS Toor, LE White, R Byrd, H Bevan, E Werner,
E Lowe, W Owen, L Pegram

2006.  XXXXX; A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel   Group Study of XXXXX Flexibly Dosed in the Treatment of Children and Adolescents with
Autistic Disorder.  Principal Investigator:  DW Lewis; Sub-Investigators:  LM Frank, RS Northam, SS Toor, LE White, MS Warren, Van de Water, E Paradiso, TK Swack

2006.  XXXXX; A 52-Week, Open-Label, Multicenter Study of    the Safety and Tolerability of XXXXX Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder.  Principal Investigator:  DW Lewis; Sub-Investigators:  LM Frank, RS Northam, SS Toor, LE White, MS Warren, VVan de Water, E Paradiso, TK Swack

2006.  XXXXX; XXXXX for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children.  Principal Investigator:  DW Lewis;   Sub-Investigators:  LM Frank, RS Northam, SS Toor, LA Batres, GE Kobak, VM Tsou, LK Willis